October 21, 2020

The Niche

Knoepfler lab stem cell blog

Doug Melton

8 min read

ViaCyte is one of the most exciting stem cell and regenerative medicine biotech companies so I like to try to check in with them regularly. Today’s post is my new interview with ViaCyte leader Paul Laikind on recent developments. We had a great chat about the science and how things are looking upbeat for the company, which is growing (a heads up for stem cell biologists who may be job hunting). You can read my previous interview with them from about a year ago …Read More

3 min read

What happens when one of the most exciting stem cell biotechs ViaCyte teams up with a firm like CRISPR Therapeutics to use a combination of gene editing and cell therapy? Hopefully a synergistic partnership emerges that in this case can develop an effective stem cell-based therapy for diabetes. You can see a press release on the news. (Update, see my new interview after the news broke with ViaCyte CEO Paul Laikind) ViaCyte has been a frequent subject of posts on The Niche related to …Read More

1 min read

Stem Cell & Regenerative Medicine field researchers move around to different places fairly often. It is interesting to note trends and also see who received what kinds of awards and such. Below is a list of some recent movers and shakers. George Daley got the ISSCR Public Service Award (you can see other ISSCR Awards here). The new ISSCR President is Hans Clevers. The new and first CEO of ARM is Janet Lambert. Former CIRM President Randy Mills is now leading the National Marrow Donor …Read More

2 min read

Clinical research on Type I Diabetes is one of the most exciting and promising areas of stem cells and regenerative medicine for human disease. Two of the coolest companies out there in this arena have been ViaCyte and BetaLogics (owned by J&J). For more on ViaCyte see my interview with President and CEO Paul Laikind from 2015. Today brings great news for ViaCyte on two fronts. Incidentally, this gives me a correct prediction on my Top 20 stem cell predictions for 2016. First, it has …Read More